Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

Male

	Treatment Group (mg/kg)			
	10 IV Plasma ^a	30 IV Plasma ^a	90 IV Plasma ^a	
Cmax_pred (ug/mL)	13.3	39.4	139	
Tmax_pred (hour)				
k01 (hour ⁻¹)				
k01 Half-life (hour)				
k10 (hour-1)	0.052	0.056	0.049	
k10 Half-life (hour)	13.4	12.3	14.2	
Cl (mL/(hr*kg))	39	43	32	
V1 (mL/kg)	754	761	649	
MRT (hour)	19	15	20	
AUCinf_pred (ug*hr/mL)	256	655	2847	
F				

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

Male

	Treatment Group (mg/kg)				
	36 Gavage Plasma ^{b,c}	300 Gavage Plasma ^{b,d}	600 Gavage Plasma ^{b,e}		
			-		
Cmax_pred (ug/mL)	49.6	301.3	823.2		
Tmax_pred (hour)	1.9	2.4	1.7		
k01 (hour-1)	1.97	1.7	2.5		
k01 Half-life (hour)	0.35	0.42	0.28		
k10 (hour-1)	0.47	0.037	0.037		
k10 Half-life (hour)	14.8	18.8	18.5		
Cl (mL/(hr*kg))	39	38	39		
V1 (mL/kg)	662	913	684		
MRT (hour)	23	25	24		
AUCinf_pred (ug*hr/mL)	1201	11099	24717		
F	1.3	1.4	1.6		

F

Toxicokinetics Data Summary Compound: Formamide/ Analyte: Formamide CAS Number: 75-12-7

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

Female Treatment Group (mg/kg) 10 IV Plasma^a 30 IV Plasma^a 90 IV Plasma^a Cmax_pred (ug/mL) 12.2 41.3 141 Tmax pred (hour) k01 (hour-1) k01 Half-life (hour) k10 (hour-1) 0.055 0.070 0.066 k10 Half-life (hour) 12.7 10.0 10.4 Cl (mL/(hr*kg)) 45 51 43 V1 (mL/kg) 821 727 640 19 13 18 MRT (hour) AUCinf_pred (ug*hr/mL) 227 573 2284

k10 (hour-1)

V1 (mL/kg)

MRT (hour)

F

k10 Half-life (hour) Cl (mL/(hr*kg))

AUCinf_pred (ug*hr/mL)

Toxicokinetics Data Summary Compound: Formamide/ Analyte: Formamide CAS Number: 75-12-7

0.055

12.6

17.9

1.2

45

1025

7961

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

0.044

15.8

20.4

1.4

44

755

18977

Female Treatment Group (mg/kg) 36 Gavage Plasma^{b,f} 300 Gavage Plasma^{b,g} 600 Gavage Plasma^{b,h} 269.4 Cmax_pred (ug/mL) 50.5 752.6 Tmax pred (hour) 1.5 1.5 1.3 k01 (hour-1) 2.5 2.6 3.6 k01 Half-life (hour) 0.28 0.26 0.19

0.63

11.0

46

19

1.2

648

934

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

LEGEND

MODELING SOFTWARE

WinNonlin, Version 1

MODELING METHOD & BEST FIT MODEL

^aWinNonlin (Version 1, SCI, Cary, North Carolina) estimated elimination half lives (K10_Half-life), volumes of distribution (V shown as V1), and clearance (CI). Model independent methods (Statistical Moment, CHANKIN software, Chan, K.K.J., Wnuck, K., Bell, C.L., Comp. Prog. Biomed., 1986.) were used to estimate mean residence time (MRT) and area under the plasma concentration-time curve (AUCo-inf). one compartment model with first order elimination

^bWinNonlin (Version 1, SCI, Cary, North Carolina) estimated Cmax, Tmax, and elimination and absorption half-lives. Model independent methods (CHANKIN) were used to estimate mean residence time (MRToral), mean absorbance time (MAT) and area under the plasma concentration-time curve (AUCo-inf). one compartment model with first order absorption and elimination

EXCEPTIONS

^cExtravascular mean absorption time (MAT) is 4.8 hours. ^dExtravascular mean absorption time (MAT) is 7.1 hours. ^eExtravascular mean absorption time (MAT) is 5.6 hours. ^fExtravascular mean absorption time (MAT) is 1.5 hours. ^gExtravascular mean absorption time (MAT) is 0.9 hours. ^hExtravascular mean absorption time (MAT) is 3.4 hours.

ANALYTE

Formamide

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

TK PARAMETERS

- Cmax_pred = Observed or Predicted Maximum plasma (or tissue) concentration
- Tmax_pred = Time at which Cmax predicted or observed occurs
- k01 = Absorption rate constant, ka
- k01 Half-life = Half-life of the absorption process to the central compartment
- k10 = Elimination rate constant from the central compartment also ke or kelim
- k10 Half-life = Half-life for the elimination process from the central compartment
- CI = Clearance, includes total clearance
- V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution NCA, Vapp apparent volume of distribution for intravenous studies
- MRT = Mean residence time
- AUCinf_pred = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity
- F = Bioavailability, absolute bioavailability

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

TK PARAMETERS PROTOCOL

ANALYSIS METHOD

Only data that were above the limit of detection were used in calculations. WinNonlin software was used for modeling. Also, model independent methods (Statistical Moment, CHANKIN software, Chan, K.K.J., Wnuck, K., Bell, C.L., Comp. Prog. Biomed., 1986.) were used to estimate mean residence time (MRT) and area under the plasma concentration-time curve (AUCo-inf), where area under the plasma concentration-time curve (extrapolated to infinity) is equal to the sum of AUCo-t, calculated using the trapezoidal rule, and AUCt-inf, (where AUC t-inf = C(t)/ke, and ke, is the first-order elimination rate constant).

TK_INTRAVENOUS PLASMA

10 mg/kg, 30 mg/kg, 90 mg/kg Male and Female

Animals were administered a single dose by intravenous injection or oral gavage. Three rats or mice/route/dose/sex were sampled at each of 14 or for intravenously administered rats, 16 time points. Final time point ranged from 48-96 hours post-dosing. Plasma samples were analyzed by gas chromatography with thermionic specific detector (TSD) using 12 pentachloropyridine as internal standard. The limit of detection (LOD) of formamide is 0.1 ug/mL and the experimental limit of quantitation (ELOQ) is 1.1 ug/mL.

ANALYSIS METHOD

Only data that were above the limit of detection were used in calculations. WinNonlin software used for modeling. Also, model independent methods (Statistical Moment, CHANKIN software, Chan, K.K.J., Wnuck, K., Bell, C.L., Comp. Prog. Biomed., 1986.) were used to estimate mean residence time (MRT) and area under the plasma concentration-time curve (AUCo-inf), where area under the plasma concentration-time curve (AUCo-inf), where area under the plasma concentration-time curve (AUCo-inf), where area under the plasma concentration-time curve (extrapolated to infinity) is equal to the sum of AUCo-t, calculated using the trapezoidal rule, and AUCt-inf, (where AUC t-inf = C(t)/ke, and ke, is the first-order elimination rate constant). Bioavailability (F) is equal to (Dose normalized AUCO-inf oral) / (Mean dose normalized AUCo-inf i.v.).

Experiment Number: S0613 Route: Gavage, IV Species/Strain: Rats/Fischer 344 Toxicokinetics Data Summary Compound: Formamide/ Analyte: Formamide CAS Number: 75-12-7 Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Midwest Research Institute

TK PARAMETERS PROTOCOL (cont'd)

TK_GAVAGE PLASMA

36 mg/kg, 300 mg/kg, 600 mg/kg Male and Female

Animals were administered a single dose by intravenous injection or oral gavage. Three rats or mice/route/dose/sex were sampled at each of 14 or for intravenously administered rats, 16 time points. Final time point ranged from 48-96 hours post-dosing. Plasma samples were analyzed by gas chromatography with thermionic specific detector (TSD) using 12 pentachloropyridine as internal standard. The limit of detection (LOD) of formamide is 0.1 ug/mL and the experimental limit of quantitation (ELOQ) is 1.1 ug/mL.